Brainomix Targets U.S. Expansion with £4.8M Series C Extension in 2026

LONDON, February 24, 2026 — Oxford-based healthtech innovator Brainomix has announced the successful closure of an additional £4.8 million in its Series C funding round, according to a report by TechFundingNews. This infusion of capital brings the total raised in this round to £18.8 million and sets the stage for the company’s ambitious U.S. expansion efforts. Led by returning investors Parkwalk and Hostplus via the IP Group Hostplus Innovation Fund, with new participation from U.S.-based Modi Ventures, the funding will bolster Brainomix’s AI-powered imaging solutions for stroke and lung fibrosis care.

Executive Summary

• Brainomix, an Oxford-based AI healthtech company, secured £4.8M in Series C extension funding.
• The funding round was co-led by Parkwalk, Hostplus, and new investor Modi Ventures.
• The funds will support Brainomix’s entry into the U.S. market and enhance its AI imaging platforms.
• Brainomix’s AI tools target stroke and lung fibrosis diagnostics, improving precision medicine globally.

Key Developments

Brainomix, founded by Dr. Michalis Papadakis and a team from the University of Oxford, is advancing healthcare diagnostics with its AI-driven imaging platforms. The company’s flagship product, Brainomix 360 Stroke, is the world’s first fully automated system to assist clinicians in stroke assessment, from diagnosing stroke type to evaluating its severity and deciding on patient transfer and treatment pathways. Additionally, its e-Lung platform leverages AI biomarkers to detect and monitor pulmonary fibrosis, enhancing early treatment and clinical decision-making.

With the recent £4.8 million Series C extension, the company plans to expedite the adoption of its technology in the U.S. market, which is a critical region for growth. The funds will also be allocated toward scaling customer support and accelerating integrations with hospital networks in both the U.S. and Europe. Brainomix’s solutions have already secured multiple FDA clearances and are operational in over 20 countries, showcasing a strong foundation of regulatory approvals and clinical validation.

This funding round also marks the entry of Modi Ventures, a U.S.-based investor, into the company’s investor portfolio. This strategic addition suggests a targeted focus on establishing a foothold in the North American market, where healthcare systems are heavily investing in AI-driven diagnostic tools to improve precision and reduce treatment delays.

Market Context

AI in healthcare has witnessed exponential growth, particularly in imaging and diagnostics, where technologies like Brainomix’s platforms are reshaping clinical workflows. For more on [related ai developments](/apple-signals-new-product-launch-strategy-shift-by-2026-23-february-2026). According to a report by Bloomberg, the global market for AI healthcare applications is expected to exceed $67 billion by 2027, driven by the increasing prevalence of chronic diseases and the need for faster, more accurate diagnostics.

Brainomix is entering a competitive landscape dominated by players such as Viz.ai, Aidoc, and RapidAI. However, its combination of broad imaging capabilities, strong regulatory credentials, and a diversified clinical focus extending beyond stroke care gives it a unique edge. The U.S. healthcare market, in particular, presents significant opportunities due to its high demand for scalable solutions that can address gaps in diagnostic consistency and speed.

BUSINESS 2.0 Analysis

Brainomix’s latest funding milestone reflects broader trends in healthcare innovation, where AI is no longer a luxury but an operational necessity. The company’s ability to secure backing from both European and U.S. investors underscores confidence in its technology and market potential. By targeting stroke and pulmonary fibrosis—two conditions with high diagnostic variability and impact—Brainomix is addressing critical gaps in care delivery.

What sets Brainomix apart is its focus on full automation and integration into existing hospital workflows, a feature that reduces the learning curve for healthcare providers. Its regulatory approvals in over 20 countries, including FDA clearances, position it as a trusted player in a crowded market. Furthermore, the U.S. expansion is a logical next step, given the country’s advanced adoption of AI in healthcare and its substantial investment in digital transformation initiatives.

However, challenges remain. Competing against well-funded rivals like Viz.ai and Aidoc will require sustained innovation and strategic partnerships. Additionally, the U.S. market’s complex regulatory environment and fragmented healthcare systems could pose hurdles. Yet, Brainomix’s demonstrated success in Europe and its focus on precision medicine provide a solid foundation for overcoming these barriers.

Why This Matters for Industry Stakeholders

For healthcare providers, Brainomix’s AI imaging platforms offer an opportunity to improve patient outcomes while reducing diagnostic errors and delays. By automating complex imaging workflows, the technology empowers clinicians to make faster, more informed decisions.

For investors, the company’s dual focus on stroke and lung fibrosis diagnostics taps into high-growth segments of the healthcare market. For more on [related ai developments](/india-signals-deep-tech-growth-with-new-startup-rules-2026-8-february-2026). The addition of Modi Ventures as a U.S.-based investor strengthens Brainomix’s positioning for future growth in North America.

For regulators, Brainomix’s existing FDA clearances and strong clinical validation provide a benchmark for how AI can be safely and effectively integrated into healthcare systems.

Forward Outlook

Looking ahead, Brainomix is well-positioned to capitalize on the growing demand for AI in healthcare. Its U.S. expansion strategy will likely include partnerships with leading hospital networks and increased investment in customer support and training. The company’s diversified product portfolio also opens doors for future innovations in related fields, potentially extending its reach into other high-impact diagnostic areas.

However, navigating the complexities of the U.S. healthcare market will require careful planning and execution. Success will depend on the company’s ability to demonstrate measurable improvements in clinical outcomes and cost efficiency, key metrics for adoption in the competitive U.S. landscape.

Key Takeaways

• Brainomix secures £4.8M in Series C extension, bringing total funding to £18.8M.
• Funds will support U.S. expansion and enhance AI imaging platforms for stroke and lung fibrosis.
• New investor Modi Ventures signals a strategic focus on North American growth.
• Brainomix’s FDA-cleared products are operational in over 20 countries, showcasing strong validation.

References

1. TechFundingNews
2. Bloomberg
3. Financial Times
4. Reuters
5. More AI Coverage